Published 13 days ago • loading... • Updated 13 days ago

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study - Mira Pharmaceuticals (NASDAQ:MIRA)

Summary by Benzinga

MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in early 2026.

2 Articles

All

Left

Center

Right

Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal

13 days ago

MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in early 2026.

13 days ago·New York, United States

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources2

Leaning Left0Leaning Right1Center1Last Updated13 days agoBias Distribution

50% Center, 50% Right

50% Right

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States 13 days ago on Wednesday, April 16, 2025.

Sources are mostly out of (0)